TPSTTempest Therapeutics, Inc.
- Revenue
- —
- Operating margin
- —
- EBITDA
- —
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
4.4× less likely than average to be bought by an AI rollup
Clinical-stage biotech developing CAR-T cell therapies and small molecule cancer drug candidates. Recurring revenue 0/10 · AI-rollup fit 0/10 · Services share 1/10 · Labor intensity 2/10 · Work AI could do 1/10 · Fragmented market 1/10 How it works
Signals 0 of 15
No signals fired.
15 other checks
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo$2M medianMedian CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo—Over 10% of revenue
- Payouts exceed cash flowNo—Buybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentNo—Any vote under 80% support
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AINo—Bottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedNo—Market cap $500M–$5B
- Recurring revenueNo0 of 1010-K business scored 7+ of 10 for recurring revenue
- AI-rollup shapedNo0 of 1010-K business scored 5+ of 10 as an AI-rollup target
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo$0 netNet sales over $10M in 12 months
Financials
No XBRL financials yet.
Deal filings
| Filed | Form | Acquirer | Price | Premium |
|---|---|---|---|---|
| Nov 6, 2018 | DEFM14A | Millendo Therapeutics, Inc. | $0.11 | 107% |
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $2M | 19 | — |
| FY2024 | $2M | −$2M | 16 | — |
| FY2023 | $7M | $4M | 83 | — |